Furthermore, Frank et al. performed IgHTS on serial plasma samples from 69 patients with relapsed/refractory DLBCL (rrDLBCL) receiving anti-CD19 CAR T-cell therapy and demonstrated that pretreatment ctDNA levels significantly correlate with progression-free survival (PFS) and overall survival (OS) [39]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.